Nyxoah (XBRU:NYXH) Cash, Cash Equivalents, Marketable Securities : €44.30 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Nyxoah Cash, Cash Equivalents, Marketable Securities?

Nyxoah's quarterly cash, cash equivalents, marketable securities declined from Sep. 2023 (€72.49 Mil) to Dec. 2023 (€57.75 Mil) but then stayed the same from Dec. 2023 (€57.75 Mil) to Mar. 2024 (€44.30 Mil).

Nyxoah's annual cash, cash equivalents, marketable securities declined from Dec. 2021 (€135.51 Mil) to Dec. 2022 (€94.86 Mil) and declined from Dec. 2022 (€94.86 Mil) to Dec. 2023 (€57.75 Mil).

Nyxoah Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Nyxoah's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nyxoah Cash, Cash Equivalents, Marketable Securities Chart

Nyxoah Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

5.86

92.30

135.51

94.86

57.75

Nyxoah Quarterly Data
	Dec17	Dec18	Jun19	Dec19	Mar20	Jun20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															96.07	84.52	72.49	57.75	44.30

Nyxoah Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Nyxoah (XBRU:NYXH) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Nyxoah Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Nyxoah's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Nyxoah (XBRU:NYXH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nyxoah SA (XBRU:NYXH) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

NYXH:USA 5YI:Germany

Address

Rue Edouard Belin 12, Mont-Saint Guibert, BEL, 1435

Website

https://www.nyxoah.com

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.